These guidelines recommend routine multigene testing of all advanced NSCLC with an adenocarcinoma component for EGFR mutations and ALK and ROS1 rearrangements, together with additional genes (RET, MET, Her2, KRAS, and BRAF). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.